DOJ Declines to Prosecute Balt as Executives Face FCPA Bribery Charges

The US Department of Justice has used the Balt SAS case to send a dual message on Foreign Corrupt Practices Act enforcement. Companies that voluntarily self-disclose, cooperate fully and remediate quickly may secure a declination, but individuals tied to the same conduct remain firmly in prosecutors’ sights. That combination makes this a notable development for healthcare, life sciences and other internationally exposed sectors.

Balt SAS, a France-headquartered medical device company, resolved the investigation through a declination under Part I of the Department-wide Corporate Enforcement and Voluntary Self-Disclosure Policy. In practical terms, DOJ agreed not to prosecute the company after concluding that Balt had voluntarily reported the misconduct, provided full cooperation and undertook timely remediation. Balt will still pay around $1.2 million in disgorgement, showing that a declination does not mean a company escapes financial consequences altogether.

At the same time, prosecutors unsealed charges against David Ferrera, an executive at Balt’s US subsidiary, and Marc Tilman, a Belgium-based consultant engaged by that subsidiary. The indictment alleges that, between 2017 and 2023, the men and others paid bribes to a senior physician at a state-owned public hospital in France in order to secure hospital purchases of Balt medical devices, including endovascular embolisation coils and related products. According to DOJ, the alleged payments were disguised as consulting fees and bonuses, with sham agreements, fake invoices and personal email accounts used to conceal the scheme.

The compliance significance is clear. DOJ is highlighting that self-reporting can materially improve corporate outcomes, even in a cross-border bribery case involving a public hospital and a foreign official under the FCPA. The department expressly framed this as the first declination under its Department-wide Corporate Enforcement Policy, making it an important reference point for future enforcement discussions. For corporates, the case reinforces the value of internal investigations that move quickly enough to support timely disclosure decisions.

The facts also underline familiar but important corruption risk indicators in the healthcare sector. Third-party consultants, success-linked payments, vague service descriptions, weak invoice scrutiny and business won through state-linked hospitals remain classic red flags. The alleged use of a consultant to channel improper payments is a pattern compliance teams should recognise immediately, particularly where the end customer is a public institution and the decision-maker is capable of being treated as a foreign official for FCPA purposes.

Another key point is the cross-border enforcement angle. DOJ coordinated its outcome with France’s Parquet National Financier, which entered into a parallel resolution with Balt on 19 March 2026. That coordination reflects the increasingly international nature of anti-bribery enforcement and the growing expectation that companies respond consistently across multiple jurisdictions. For firms operating in Europe and the US, investigations can no longer be approached as single-country events.

DOJ’s explanation of why Balt received a declination is also instructive. Prosecutors pointed to timely voluntary disclosure, proactive cooperation, remediation measures, disciplinary action, termination of problematic relationships, tailored compliance training for senior management and improvements to internal controls. They also noted the absence of aggravating factors strong enough to outweigh those steps. This gives compliance officers a fairly direct checklist of what enforcement authorities expect to see when misconduct is uncovered.

The case therefore lands as both an incentive and a warning. The incentive is that prompt disclosure and credible remediation can substantially reduce corporate exposure. The warning is that declinations for companies do not shield executives, consultants or other intermediaries from prosecution. Businesses in regulated and state-facing markets should take this as a reminder to test third-party controls, payment approval processes, documentation standards and escalation procedures around public sector sales.

From a risk perspective, the healthcare industry should pay close attention. Public hospitals, physician decision-makers, distributor and consultant models, and technically specialised products often create precisely the sort of environment where commercial pressure and weak controls can combine into bribery risk. Enforcement agencies have shown repeatedly that they view these cases as priority matters, particularly where public procurement and hidden intermediaries are involved.

Overall, the Balt matter is best understood as a modern FCPA enforcement template. DOJ is rewarding corporate behaviour it wants to encourage while continuing to pursue the individuals allegedly responsible for the misconduct. For multinational companies, especially those selling into public healthcare systems, the lesson is straightforward: investigate early, disclose fast where appropriate, remediate convincingly and assume authorities on both sides of the Atlantic will compare notes.

Read the press release here.